[go: up one dir, main page]

MX2022003912A - Composicion farmaceutica que puede usarse para la prevencion y/o el tratamiento de la hemofilia a adquirida, y producto que comprende la composicion farmaceutica. - Google Patents

Composicion farmaceutica que puede usarse para la prevencion y/o el tratamiento de la hemofilia a adquirida, y producto que comprende la composicion farmaceutica.

Info

Publication number
MX2022003912A
MX2022003912A MX2022003912A MX2022003912A MX2022003912A MX 2022003912 A MX2022003912 A MX 2022003912A MX 2022003912 A MX2022003912 A MX 2022003912A MX 2022003912 A MX2022003912 A MX 2022003912A MX 2022003912 A MX2022003912 A MX 2022003912A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
prevention
treatment
product
acquired hemophilia
Prior art date
Application number
MX2022003912A
Other languages
English (en)
Inventor
Koichiro Yoneyama
Sayaka Nagami
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority claimed from PCT/JP2020/038069 external-priority patent/WO2021070885A1/ja
Publication of MX2022003912A publication Critical patent/MX2022003912A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Los presentes inventores descubrieron que la administración de una composición farmacéutica que comprende emicizumab de acuerdo con un régimen de administración predeterminado tiene el potencial de prevenir y/o tratar eficazmente la hemofilia A adquirida.
MX2022003912A 2019-10-11 2020-10-08 Composicion farmaceutica que puede usarse para la prevencion y/o el tratamiento de la hemofilia a adquirida, y producto que comprende la composicion farmaceutica. MX2022003912A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019188099 2019-10-11
JP2020011992 2020-01-28
PCT/JP2020/038069 WO2021070885A1 (ja) 2019-10-11 2020-10-08 後天性血友病ａの予防および／または治療に用いられる医薬組成物、および当該医薬組成物を含む製品

Publications (1)

Publication Number Publication Date
MX2022003912A true MX2022003912A (es) 2022-04-20

Family

ID=74673603

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003912A MX2022003912A (es) 2019-10-11 2020-10-08 Composicion farmaceutica que puede usarse para la prevencion y/o el tratamiento de la hemofilia a adquirida, y producto que comprende la composicion farmaceutica.

Country Status (10)

Country Link
US (1) US20220305122A1 (es)
EP (1) EP4043033A4 (es)
JP (1) JP6836696B1 (es)
KR (1) KR20220082000A (es)
CN (1) CN114599391A (es)
AU (1) AU2020364698A1 (es)
CA (1) CA3152701A1 (es)
CR (1) CR20220198A (es)
IL (1) IL292106A (es)
MX (1) MX2022003912A (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI820000B (zh) 2016-04-28 2023-11-01 日商中外製藥股份有限公司 含抗體製劑
AR113816A1 (es) 2017-11-01 2020-06-17 Chugai Pharmaceutical Co Ltd Variantes e isoformas de anticuerpos con actividad biológica reducida
WO2025134341A1 (ja) * 2023-12-22 2025-06-26 中外製薬株式会社 抗体の製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
US20080075712A1 (en) 2003-10-14 2008-03-27 Kunihiro Hattori Double Specific Antibodies Substituting For Functional Proteins
DK1876236T3 (da) 2005-04-08 2014-10-20 Chugai Pharmaceutical Co Ltd Antistof som funktionel erstatning for blodkoagulationsfaktor VIII
RU2620071C2 (ru) 2010-11-17 2017-05-22 Чугаи Сеияку Кабушики Каиша Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
TWI831106B (zh) * 2014-06-20 2024-02-01 日商中外製藥股份有限公司 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
JP7125932B2 (ja) * 2016-09-06 2022-08-25 中外製薬株式会社 凝固第ｉｘ因子および／または活性化凝固第ｉｘ因子ならびに凝固第ｘ因子および／または活性化凝固第ｘ因子を認識する二重特異性抗体の使用法

Also Published As

Publication number Publication date
JP6836696B1 (ja) 2021-03-03
JPWO2021070885A1 (es) 2021-04-15
US20220305122A1 (en) 2022-09-29
CA3152701A1 (en) 2021-04-15
KR20220082000A (ko) 2022-06-16
EP4043033A4 (en) 2023-11-08
EP4043033A1 (en) 2022-08-17
CN114599391A (zh) 2022-06-07
CR20220198A (es) 2022-06-06
AU2020364698A1 (en) 2022-04-21
IL292106A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
WO2021050953A8 (en) Compositions and methods for the delivery of therapeutic biologics for treatment of disease
PH12018500642A1 (en) Anti-garp antibody
MY189333A (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
MX2016016744A (es) Inhibidores de ezh2 para tratar linfomas.
MY201148A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
MY187540A (en) Compounds active towards bromodomains
EP4299129A3 (en) Dosing regimen for treatment of cognitive impairments with blood plasma products
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
CR20220198A (es) Composición farmacéutica que puede usarse para la prevención y/o el tratamiento de la hemofilia a adquirida, y producto que comprende la composición farmacéutica
MY201804A (en) Administration and dosage of diaminophenothiazines
PH12020552171A1 (en) Bifunctional compositions for the treatment of cancer
MX2018000546A (es) Composiciones farmaceuticas que contienen celecoxib y tramadol.
PH12022551468A1 (en) Compounds active towards nuclear receptors
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
NZ726132A (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MY198553A (en) Pharmaceutical composition comprising metformin and lobeglitazone
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12021551138A1 (en) Application of chidamide in combination with r-chop, and drug combination
WO2017010673A3 (ko) 혈관누수 증후군의 예방 또는 치료용 조성물
WO2018030881A3 (ko) 맥락막 질환의 치료를 위한 갑상선 호르몬의 용도
PH12017501918A1 (en) Multi-peptide composition
MX2023005681A (es) Composicion farmaceutica para el tratamiento contra el dolor agudo y cronico, que contiene polmacoxib y tramadol.
HK40065842A (zh) 可用於预防和/或治疗获得性血友病a的药物组合物，以及包含所述药物组合物的产品